What this Trial Is About

Researchers are evaluating the effect of l-carnitine as an add-on therapy to improve outcomes in patients with rheumatoid arthritis (RA), an inflammatory autoimmune disease that mainly affects joints like the hands, wrists, and feet. The disease is more common in females and is linked to genetic and environmental factors that trigger an autoimmune response. RA causes symmetrical joint inflammation, leading to pain, stiffness, fatigue, and sometimes affects other organs. Current treatments rely on anti-inflammatory and immune-suppressing drugs called DMARDs, but there is a need for safer, effective alternatives. This phase 2 trial compares l-carnitine supplementation with conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine. L-carnitine, a nutritional supplement known for its antioxidant and anti-inflammatory properties, is given alongside standard therapy. Participants will continue their stable DMARD treatments while adding l-carnitine. The study duration is 12 weeks. Participants will undergo assessments of disease activity using the DAS28 ESR score from enrollment through the 12-week trial period. Researchers will monitor changes in joint inflammation and overall disease activity to evaluate the impact of l-carnitine. Safety assessments will include monitoring liver and kidney function and any side effects. The study aims to provide new insights into improving RA management with an affordable supplemental treatment option.

L-carnitine Supplementation in Rheumatoid Arthritis Patients